Expectations for AI in healthcare, particularly biopharma and diagnostics, have been high for several years now. New partnerships and acquisitions may…
McAlinden Research PartnersJanuary 17, 2023
Shares of biotechnology firms focused on gene editing were slammed this week by an FDA hold placed on Verve Therapeutics'…
McAlinden Research PartnersDecember 8, 2022
Three pharma giants are in the running to purchase Horizon Therapeutics in what will likely be a larger deal than…
McAlinden Research PartnersDecember 1, 2022
Mergers and Acquisitions in the biopharma space continue to heat up, fueling a significant increase in large deals through the first 9…
McAlinden Research PartnersOctober 19, 2022
The US's first marketed CRISPR drug may be set to make its debut in a year or less, following CRISPR…
McAlinden Research PartnersSeptember 29, 2022
M&A activity is picking up among pharmaceutical firms with large cash balances. Pfizer and Amgen have each closed a multi-billion…
McAlinden Research PartnersAugust 9, 2022
Pharma giants Pfizer and Moderna just secured multi-billion dollar deals to supply the US government with more than 170 million…
McAlinden Research PartnersAugust 1, 2022
Psychedelic medicine, focused on alternative mental health therapies that utilize drugs like LSD, MDMA and psilocybin, is becoming increasingly popular…
McAlinden Research PartnersJuly 18, 2022
Last year marked one of the least active years for biopharma merger and acquisition (M&A) activity in a decade. The first…
McAlinden Research PartnersJuly 14, 2022
